TNBC - Triple-Negative Breast Cancer Clinical Trials

25 recruiting

TNBC - Triple-Negative Breast Cancer Trials at a Glance

25 actively recruiting trials for tnbc - triple-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Shanghai, New York, and Houston. Lead sponsors running tnbc - triple-negative breast cancer studies include Fudan University, First Affiliated Hospital of Zhejiang University, and Cedars-Sinai Medical Center.

Browse tnbc - triple-negative breast cancer trials by phase

Treatments under study

About TNBC - Triple-Negative Breast Cancer Clinical Trials

Looking for clinical trials for TNBC - Triple-Negative Breast Cancer? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new TNBC - Triple-Negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about TNBC - Triple-Negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

TNBC - Triple-Negative Breast Cancer
Fudan University300 enrolled1 locationNCT07551050
Recruiting
Phase 2

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Not Applicable

NearWave Optical Molecular Monitoring

Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+2 more
Indiana University15 enrolled1 locationNCT06744465
Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
University Hospital Tuebingen225 enrolled1 locationNCT05914961
Recruiting
Phase 3

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University37 enrolled2 locationsNCT07351487
Recruiting
Phase 2

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

TNBC - Triple-Negative Breast Cancer
Jules Bordet Institute20 enrolled1 locationNCT06059469
Recruiting
Phase 3

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Abramson Cancer Center at Penn Medicine300 enrolled1 locationNCT05396612
Recruiting
Not Applicable

Trop-2 Targeted PET Probes in Advanced TNBC

TNBC - Triple-Negative Breast Cancer
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT07046455
Recruiting
Phase 2

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Processa Pharmaceuticals90 enrolled13 locationsNCT06568692
Recruiting
Early Phase 1

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerLocally Advanced Triple Negative Breast Cancer
Rima Patel15 enrolled1 locationNCT06637306
Recruiting
Phase 1Phase 2

Study of LP-184 in Patients With Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265
Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Personalis Inc.422 enrolled14 locationsNCT06230185